tirzepatide surpass SURPASS-2 (NEJM 2021) was the definitive head-to-head: vs semaglutide 1.0 mg (the maximum approved T2DM dose) in 1,879 patients with type 2 diabetes. All three tirzepatide doses produced superior HbA1c reductions SURPASS-CVOT: Tirzepatide Significantly Reduces Major

Q : Are there any instructions inside the box regarding how to inject this medicine

Results from the SURPASS program's phase 3 trials indicate that tirzepatide, administered weekly in doses of 5mg, 10mg, and 15mg, significantly enhances glycemic control in T2D

Tirzepatide targets both GLP-1 and GIP receptors, with some research suggesting superior weight loss outcomes

While both compounds improve these metrics, the magnitude of change in retatrutide trials has led some researchers to suggest it may provide a more potent "reset" of metabolic syndrome markers

Final Thoughts MEDVi MEDVi represents a major advancement in accessible, medically guided weight management

Tastes better, longer Never sitting in transitfrozen when its at its best